Sanofi and Regeneron announce positive Dupixent® phase 3 atopic dermatitis data
Sanofi and Regeneron announce that detailed results from LIBERTY AD SOLO 1 and SOLO 2, two placebo-controlled Phase 3 studies evaluating investigational Dupixent® (dupilumab) in adult patients with inadequately controlled moderate-to-severe AD, were published in The NEJM. October 01, 2016